The US FDA Clears Cullinan Oncology’s IND Application of CLN-619 for Treating R/R Multiple Myeloma
Shots:
- The US FDA has cleared the company’s IND application of CLN-619 to initiate its P-I dose-escalation & expansion trial for the treatment of r/r multiple myeloma
- The company is currently evaluating CLN-619 in the P-I study both as monotx. & in combination with Keytruda to determine its safety, efficacy & PK/PD characteristics for the treatment of advanced solid tumors
- CLN-619, a humanized IgG1 mAb, restores the expression of MICA & MICB on the tumor cell surface to enhance the interaction b/w MICA & NKG2D. This produces antibody-dependent cellular toxicity (ADCC) & anti-tumor activity through various immune-mediated mechanisms
Ref: Cullinan Oncology | Image: Cullinan Oncology
Related News:- Taiho Entered into an Agreement to Acquire Cullinan for CLN-081/TAS6417 to Treat EGFR Exon20 Non-Small Cell Lung Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
